A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS)

Guillain-Barré Syndrome Clinical Trial

Official title:
A Phase III Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Patients With Guillain-Barré Syndrome

Status Withdrawn

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of crovalimab compared with placebo as an add-on therapy to intravenous immunoglobulin (IVIg) in participants with severe GBS.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05494619
Study type	Interventional
Source	Hoffmann-La Roche
Contact
Status	Withdrawn
Phase	Phase 3
Start date	November 30, 2022
Completion date	September 30, 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02221271` - Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré Syndrome	Phase 3
Withdrawn	`NCT03773328` - A Clinical Trial of CK0801 (a New Drug) In Patients With Treatment-Resistant Guillain-Barré Syndrome (GBS)	Phase 1
Active, not recruiting	`NCT01582763` - International Guillain-Barré Syndrome Outcome Study
Completed	`NCT04035135` - A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS)	Phase 1
Recruiting	`NCT05461898` - RehabGBs: Rehabilitation in People With Guillain-Barré Syndrome	N/A
Completed	`NCT02780570` - Small Volume Plasma Exchange (SVPE) for Guillain-Barré Syndrome (GBS) Patients	Phase 2
Completed	`NCT02342184` - Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome	Phase 3